Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA)

NCT01392326 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

606

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriatic Arthritis

Interventions

DRUG: Secukinumab (75 mg)
DRUG: Secukinumab (150 mg)
DRUG: Placebo Comparator

Sponsor

Novartis Pharmaceuticals